☆ 4.6 Article

Long non-coding RNA ENST00000503625 is a potential prognostic biomarker and metastasis suppressor gene in prostate cancer

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Review Cell Biology

LNCcation: lncRNA localization and function

Mary Catherine Bridges et al.

Summary: This review summarizes the current knowledge of subcellular localization of long noncoding RNAs (lncRNAs), factors controlling their localization, emerging themes, and discusses the implications of lncRNA localization on their function and cellular behavior, as well as opportunities for future research.

JOURNAL OF CELL BIOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

NONCODEV6: an updated database dedicated to long non-coding RNA annotation in both animals and plants

Lianhe Zhao et al.

Summary: NONCODE is a comprehensive database focusing on the collection and annotation of noncoding RNAs, especially long non-coding RNAs (lncRNAs) in animals. The latest version, NONCODEV6, not only covers lncRNAs in plants and animals, but also provides updated human lncRNA-disease relationships, tissue expression profiles and predicted function of lncRNAs in common plants, as well as conservation annotation of lncRNAs at transcript level for 23 plant species.

NUCLEIC ACIDS RESEARCH (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

The double-edged sword of H19 lncRNA: Insights into cancer therapy

Yun Wei Shermane Lim et al.

Summary: H19 long non-coding RNA has dual roles in cancer, acting as both an oncogene and a suppressor gene in tumor development. It plays a crucial role in cancer therapy through various mechanisms, including its applications in recombinant vectors, chemoresistance, epigenetic regulation, alteration of tumor microenvironment, and cancer immunotherapy, as well as its relationship with the tumor suppressor gene p53.

CANCER LETTERS (2021)

Add to Collection

Article Multidisciplinary Sciences

The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer

Neha Singh et al.

Summary: The long noncoding RNA H19 plays a critical role in neuroendocrine prostate cancer by promoting cellular plasticity through epigenetic reprogramming, influencing lineage plasticity and treatment resistance in prostate cancer cells.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity

Susanne G. Kidd et al.

Summary: In primary prostate cancer, high expression of SCHLAP1 serves as a robust prognostic biomarker for predicting biochemical recurrence and is associated with adverse clinicopathological characteristics. The heterogeneity of SCHLAP1 expression emphasizes the importance of analyzing multiple samples for determination of a patient's SCHLAP1 status.

NEOPLASIA (2021)

Add to Collection

Article Oncology

The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA

Xiaolei Shi et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

Add to Collection

Article Biotechnology & Applied Microbiology

Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression

Wei Zhang et al.

MOLECULAR THERAPY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine

Simeng Wen et al.

MOLECULAR CANCER (2020)

Add to Collection

Review Urology & Nephrology

The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer

Marijo Bilusic et al.

UROLOGIC CLINICS OF NORTH AMERICA (2020)

Add to Collection

Article Urology & Nephrology

External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort

Derya Tilki et al.

EUROPEAN UROLOGY (2019)

Add to Collection

Review Urology & Nephrology

Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review

Thomas Van den Broeck et al.

EUROPEAN UROLOGY (2019)

Add to Collection

Article Urology & Nephrology

Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression

Shancheng Ren et al.

EUROPEAN UROLOGY (2018)

Add to Collection

Review Oncology

Long Noncoding RNA and Cancer: A New Paradigm

Arunoday Bhan et al.

CANCER RESEARCH (2017)

Add to Collection

Article Urology & Nephrology

Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer

Rohit Mehra et al.

EUROPEAN UROLOGY (2016)

Add to Collection

Article Oncology

RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1

John R. Prensner et al.

LANCET ONCOLOGY (2014)

Add to Collection

Review Biochemistry & Molecular Biology

Long Noncoding RNAs: Cellular Address Codes in Development and Disease

Pedro J. Batista et al.

CELL (2013)

Add to Collection

Article Oncology

Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer

Shancheng Ren et al.

EUROPEAN JOURNAL OF CANCER (2013)

Add to Collection

Article Genetics & Heredity

The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex

John R. Prensner et al.

NATURE GENETICS (2013)

Add to Collection

Review Chemistry, Medicinal

Long Noncoding RNAs: Insights from Biological Features and Functions to Diseases

Xiaolei Li et al.

MEDICINAL RESEARCH REVIEWS (2013)

Add to Collection

Article Biochemistry & Molecular Biology

The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression

Thomas Derrien et al.

GENOME RESEARCH (2012)

Add to Collection

Article Biotechnology & Applied Microbiology

Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression

John R. Prensner et al.

NATURE BIOTECHNOLOGY (2011)

Add to Collection

Review Urology & Nephrology

The use of PCA3 in the diagnosis of prostate cancer

Daphne Hessels et al.

NATURE REVIEWS UROLOGY (2009)

Add to Collection

Article Urology & Nephrology

The University of California, San Francisco cancer of the prostate risk assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy

MR Cooperberg et al.

JOURNAL OF UROLOGY (2005)

Add to Collection

Article Urology & Nephrology

Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results

KA Roehl et al.

JOURNAL OF UROLOGY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.